Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosome binding domain 1 pseudogene 18 (HMGN1P18) is a processed pseudogene of the HMGN1 gene found in humans[3][4]. While pseudogenes do not encode functional proteins, HMGN1P18 can produce transcripts that may regulate the stability and expression of the mRNA of the parent HMGN1 gene through RNA competition or decoy mechanisms[1][6]. There is evidence that increased expression of HMGA1/HMGN1 pseudogenes can decrease the mRNA and protein expression of the functional gene through competition for regulatory factors, which may play a role in diseases such as type 2 diabetes by impairing insulin receptor expression[1][6]. HMGN1P18 lacks a known direct pharmacological or therapeutic relevance and is not targeted by any approved drugs. It is not a classical enzyme, receptor, or transporter, but rather a member of the broad class of pseudogenes, with potential indirect roles in gene regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosome binding domain 1 pseudogene 18 (HMGN1P18).